Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Honeysuckle (Lonicera japonica) has been traditionally used in Chinese medicine for the treatment of febrile illnesses, including flu-like symptoms. In recent years, scientific studies have begun to explore and partially validate its antiviral properties, particularly in the context of influenza. Several laboratory and animal studies have reported that honeysuckle contains compounds such as chlorogenic acid and a microRNA called MIR2911, which may inhibit the replication of influenza A viruses. Notably, a 2014 study published in Cell Research demonstrated that MIR2911 from honeysuckle decoction could directly target and suppress influenza A virus genes, reducing viral replication in mice. Additional in vitro studies have found that honeysuckle extracts can inhibit various strains of influenza and reduce inflammation associated with infection. However, while these findings are promising, they are primarily based on preclinical research. There is a lack of large-scale, high-quality human clinical trials to confirm the efficacy and safety of honeysuckle for treating influenza in humans. Traditional use and emerging mechanistic data support its potential, but more robust clinical evidence is needed before honeysuckle can be considered a proven adjunct or alternative treatment for influenza. Thus, the evidence can be rated as moderate (3/5), with scientific validation supplementing a long history of traditional use.

More about honeysuckle
More about Influenza

Other ingredients used for Influenza

Other health conditions supported by honeysuckle

Products containing honeysuckle

Metagenics Essential Defense®